Drug Profile
Research programme: small molecule therapeutics - RAPT Therapeutics
Alternative Names: CCR4 inhibitors - RAPT Therapeutics; GCN2 inhibitors - RAPT Therapeutics; GCN2 program - RAPT Theraperutics; HPK1 Inhibitors - RAPT Therapeutics; MDSC inhibitors - RAPT Theraperutics; Myeloid-derived suppressor cell inhibitors - RAPT Therapeutics; Regulatory T-cell inhibitors - RAPT Therapeutics; USP7 inhibitors - RAPT TherpaeuticsLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator FLX Bio
- Developer RAPT Therapeutics
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action CCR4 receptor antagonists; EIF2AK4 protein inhibitors; Hematopoietic progenitor kinase 1 inhibitors; Regulatory T lymphocyte inhibitors; USP7 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours